PMID- 26640805
OWN - NLM
STAT- MEDLINE
DCOM- 20161005
LR  - 20220318
IS  - 2314-6753 (Electronic)
IS  - 2314-6745 (Print)
VI  - 2016
DP  - 2016
TI  - Effects of Liraglutide Combined with Short-Term Continuous Subcutaneous Insulin 
      Infusion on Glycemic Control and Beta Cell Function in Patients with Newly 
      Diagnosed Type 2 Diabetes Mellitus: A Pilot Study.
PG  - 6839735
LID - 10.1155/2016/6839735 [doi]
LID - 6839735
AB  - The objective of this paper is to investigate the effects of liraglutide in 
      combination with short-term continuous subcutaneous insulin infusion (CSII) 
      therapy on glycemic control and beta cell function in patients with newly 
      diagnosed type 2 diabetes mellitus (T2DM). Thirty-nine eligible newly diagnosed 
      T2DM patients were recruited and randomized to receive either of two therapies: 
      short-term CSII alone (CSII alone group) or CSII in combination with liraglutide 
      (CSII + Lira group) for 12 weeks. Blood glucose control, homeostasis model 
      assessment (HOMA) indices, and acute insulin response (AIR) were compared between 
      the two groups. The patients in CSII + Lira group achieved euglycemia with 
      equivalent insulin dosage in shorter time (1 (0) versus 2 (3) days, P = 0.039). 
      HbA1c at the end of study was comparable between two groups (6.3 +/- 0.7% versus 
      6.0 +/- 0.5%, for CSII alone group and CSII + Lira group, resp., P = 0.325). The 
      increment of AIR was higher in CSII + Lira group (177.58 (351.57) muU . min/mL 
      versus 58.15 (51.30) muU . min/mL, P < 0.001). However, after stopping 
      liraglutide, its effect on beta cell function disappeared completely. Liraglutide 
      combined with short-term CSII was effective in further improving beta cell 
      function, but the beneficial effects did not sustain after suspension of the 
      therapy.
FAU - Ke, Weijian
AU  - Ke W
AD  - Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of 
      Sun Yat-sen University, Guangzhou 510080, China.
FAU - Liu, Liehua
AU  - Liu L
AD  - Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of 
      Sun Yat-sen University, Guangzhou 510080, China.
FAU - Liu, Juan
AU  - Liu J
AD  - Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of 
      Sun Yat-sen University, Guangzhou 510080, China.
FAU - Chen, Ailing
AU  - Chen A
AD  - Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of 
      Sun Yat-sen University, Guangzhou 510080, China.
FAU - Deng, Wanping
AU  - Deng W
AD  - Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of 
      Sun Yat-sen University, Guangzhou 510080, China.
FAU - Zhang, Pengyuan
AU  - Zhang P
AD  - Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of 
      Sun Yat-sen University, Guangzhou 510080, China.
FAU - Cao, Xiaopei
AU  - Cao X
AD  - Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of 
      Sun Yat-sen University, Guangzhou 510080, China.
FAU - Liao, Zhihong
AU  - Liao Z
AD  - Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of 
      Sun Yat-sen University, Guangzhou 510080, China.
FAU - Xiao, Haipeng
AU  - Xiao H
AD  - Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of 
      Sun Yat-sen University, Guangzhou 510080, China.
FAU - Liu, Jianbin
AU  - Liu J
AD  - Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of 
      Sun Yat-sen University, Guangzhou 510080, China.
FAU - Li, Yanbing
AU  - Li Y
AD  - Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of 
      Sun Yat-sen University, Guangzhou 510080, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20151110
PL  - England
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 839I73S42A (Liraglutide)
SB  - IM
MH  - Adult
MH  - Blood Glucose/*metabolism
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/*therapeutic use
MH  - Infusions, Subcutaneous
MH  - Insulin/administration & dosage/*therapeutic use
MH  - Insulin-Secreting Cells/*drug effects/metabolism
MH  - Liraglutide/administration & dosage/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Treatment Outcome
PMC - PMC4657099
EDAT- 2015/12/08 06:00
MHDA- 2016/10/07 06:00
PMCR- 2015/11/10
CRDT- 2015/12/08 06:00
PHST- 2015/02/13 00:00 [received]
PHST- 2015/04/01 00:00 [accepted]
PHST- 2015/12/08 06:00 [entrez]
PHST- 2015/12/08 06:00 [pubmed]
PHST- 2016/10/07 06:00 [medline]
PHST- 2015/11/10 00:00 [pmc-release]
AID - 10.1155/2016/6839735 [doi]
PST - ppublish
SO  - J Diabetes Res. 2016;2016:6839735. doi: 10.1155/2016/6839735. Epub 2015 Nov 10.